QNRXQuoin Pharmaceuticals, Ltd.

Nasdaq quoinpharma.com


$ 1.14 $ -0.03 (-2.56 %)    

Tuesday, 10-Sep-2024 08:17:50 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 0.96
$ 1.17
$ 1.09 x 100
$ 1.14 x 100
$ 1.12 - $ 1.17
$ 0.48 - $ 6.18
4,005,522
na
76,415
$ 2.57
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-14-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-15-2023 12-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 quoin-pharmaceuticals-ceo-michael-myers-acquired-a-total-of-37894-adss-at-prices-ranging-from-0619-07974-per-ads-similarly-coo-denise-carter-acquired-a-total-of-37735-adss-at-prices-between-06253-07965-per-ads

Quoin Pharmaceuticals (NASDAQ:QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializi...

 quoin-pharmaceuticals-initiates-pediatric-clinical-study-for-peeling-skin-syndrome-in-new-zealand

Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric pat...

 quoin-pharmaceuticals-q1-eps-111-compared-with-409-yoy-quoin-had-approximately-147m-in-cash--equivalents-as-of-march-31-2024

Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate ...

 quoin-pharmaceuticals-received-written-notice-from-nasdaq-regarding-minimum-bid-price-requirement

-SEC Filing

 maxim-group-maintains-buy-on-quoin-pharmaceuticals-lowers-price-target-to-4

Maxim Group analyst Naz Rahman maintains Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy and lowers the price target from $15...

 quoin-pharmaceuticals-q4-2023-gaap-eps-208-beats-231-estimate

Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(2.08) per share which beat the analyst consensus estimate of...

 earnings-scheduled-for-march-13-2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

 crude-oil-down-1-dave-shares-jump-after-q4-results

U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 350 points on Tuesday. The Dow traded do...

 why-sophia-genetics-shares-are-trading-lower-by-19-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expect...

 nasdaq-down-250-points-ism-services-pmi-falls-in-february

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow tr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION